Skip to main content
SpringerLink
Log in

Telmisartan/Amlodipine

Single-Pill Combination in Hypertension

  • Adis Drug Profile
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Telmisartan/amlodipine is a single-pill combination of telmisartan, an angiotensin II receptor antagonist, and amlodipine, a dihydropyridine calcium channel antagonist, which is taken orally once daily for the treatment of hypertension.

In the US and the EU, single-pill telmisartan/amlodipine can be used as a replacement for separate telmisartan and amlodipine tablets, and by patients not achieving BP goals with amlodipine monotherapy. In addition, the US indication includes patients not achieving BP goals with telmisartan (or another angiotensin II receptor antagonist or calcium channel antagonist other than amlodipine) alone, and as initial therapy in patients considered likely to require multiple drugs to achieve their BP goals.

In an 8-week, randomized, double-blind, factorial-design, placebo-controlled, multicenter study in adult patients with hypertension (n =1461), mean DBP was reduced from baseline to a significantly greater extent in recipients of telmisartan 40 or 80mg/day plus amlodipine 5 or 10mg/day than in those receiving equivalent dosages of telmisartan or amlodipine monotherapy.

Single-pill telmisartan/amlodipine recipients had significantly greater reductions in BP than telmisartan or amlodipine monotherapy recipients in an 8-week, randomized, double-blind, multicenter study in adult patients with severe hypertension (n = 858), and in four 8-week, randomized, double-blind, multicenter trials in patients who had not responded to amlodipine (n = 1097, 947, and 531) or telmisartan (n = 314) monotherapy.

Telmisartan/amlodipine was generally well tolerated in clinical trials, including two 36-week follow-up studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Fig. 3

Similar content being viewed by others

References

  1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003 May 21; 289(19): 2560–72.

    Google Scholar 

  2. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008 Aug; 24(8): 2389–401.

    Article  PubMed  CAS  Google Scholar 

  3. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 2008 Jan; 10(1 Suppl. 1): 27–32.

    Article  CAS  Google Scholar 

  4. Plosker GL, Robinson DM. Amlodipine/valsartan: fixed-dose combination in hypertension. Drugs 2008; 68(3): 373–81.

    Article  PubMed  CAS  Google Scholar 

  5. Sanfor M, Keam SJ. Olmesartan medoxomil/amlodipine. Drugs 2009; 69(6): 717–29.

    Article  Google Scholar 

  6. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008; 28(11): 713–34.

    Article  PubMed  CAS  Google Scholar 

  7. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010 Feb; 55(2): 399–407.

    Article  PubMed  CAS  Google Scholar 

  8. Bangalor S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007 Aug; 120(8): 713–9.

    Article  Google Scholar 

  9. Dickso M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008; 8(1): 45–50.

    Article  Google Scholar 

  10. Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens (Greenwich) 2010 Jan; 12(1): 40–6.

    Article  CAS  Google Scholar 

  11. McClellan KJ, Markham A. Telmisartan. Drugs 1998 Dec; 56(6): 1039–44.

    Article  PubMed  CAS  Google Scholar 

  12. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61(10): 1501–29.

    Article  PubMed  CAS  Google Scholar 

  13. Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension [published erratum appears in Drugs 2006; 66 (15): 1987]. Drugs 2006 Oct; 66(1): 51–83.

    Article  PubMed  CAS  Google Scholar 

  14. Murdoch D, Heel RC. Amlodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991; 41(3): 478–505.

    Article  PubMed  CAS  Google Scholar 

  15. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50(3): 560–86.

    Article  PubMed  CAS  Google Scholar 

  16. Plosker GL, White WB. Telmisartan/hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension. Drugs 2008; 68(13): 1877–99.

    Article  PubMed  CAS  Google Scholar 

  17. Frampton JE, Scott LJ. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. Am J Cardiovasc Drugs 2009; 9(5): 309–30.

    Article  PubMed  CAS  Google Scholar 

  18. McKeage K, Siddiqui MAA. Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am J Cardiovasc Drugs 2008; 8(1): 51–67.

    Article  PubMed  CAS  Google Scholar 

  19. Fenton C, Keating GM, Scott LJ. Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. Drugs 2003; 63(19): 2013–26.

    Article  PubMed  CAS  Google Scholar 

  20. Twynsta® (telmisartan/amlodipine) tablets: US prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc., 2009 Oct.

  21. Twynsta (telmisartan/amlodipine) 40mg/5mg, 80mg/5mg, 40mg/10mg and 80mg/10mg tablets: EU summary of product characteristics. Ingelheim am Rhein, Germany: Boehringer Ingelheim International GmbH, 2010.

  22. Fogari R, Derosa G, Zoppi A, et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 2007 Apr; 20(4): 417–22.

    Article  PubMed  CAS  Google Scholar 

  23. Fogari R, Preti P, Lazzari P, et al. Antiproteinuric effect of telmisartan/ amlodipine versus losartan/amlodipine combination in microalbuminuric hypertensive patients with type 2 diabetes [abstract no. P4.120]. J Hypertens 2009; 27 Suppl. 3: S71.

    Google Scholar 

  24. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004 May 4; 109(17): 2054–7.

    Google Scholar 

  25. Inoue T, Node K. Telmisartan as a metabolic sartan for targeting vascular failure. Expert Opin Pharmacother 2008 Jun; 9(8): 1397–406.

    Article  PubMed  CAS  Google Scholar 

  26. Sanchez RA, Masnatta LD, Pesiney C, et al. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens 2008 Dec; 26(12): 2393–8.

    Article  PubMed  CAS  Google Scholar 

  27. Veronesi M, Cicero AFG, Prandin MG, et al. Effects of telmisartan and bisoprolol on blood pressure, peripheral haemodynamic and lipid profile in statin-treated hypertensive hypercholesterolaemic patients. High Blood Press Cardiovasc Prev 2009; 16(1): 7–12.

    Article  CAS  Google Scholar 

  28. Ono Y, Nakaya Y, Bando S, et al. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function. Int Heart J 2009 Jan; 50(1): 73–83.

    Article  PubMed  CAS  Google Scholar 

  29. Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009 Jul 7; 151(1): 1–10, W1–2.

    Google Scholar 

  30. Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008 Aug; 74(3): 364–9.

    Article  PubMed  CAS  Google Scholar 

  31. Stangier J, Su C-APF. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J Clin Pharmacol 2000 Dec; 40 (12 Pt 1): 1347–54.

    Google Scholar 

  32. Tanswell P, Kunz U, Harada A, et al. Pharmacokinetics of telmisartan after repeated oral dosing are not altered by concomitant administration of amlodipine [abstract no. P27.338]. J Hypertens 2009; 27 Suppl. 3: S282–283. Plus poster presented at the 19th European Meeting on Hypertension; 2009 Jun 13–16; Milan.

    Google Scholar 

  33. Micardis® (telmisartan) tablets: US prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc., 2009 Oct.

  34. Norvasc® (amlodipine besylate) tablets for oral administration: US prescribing information. New York: Pfizer Labs, 2010 Jan.

  35. Micardis (telmisartan) 20/40/80mg tablets: EU summary of product characteristics. Ingelheim am Rhein, Germany: Boehringer Ingelheim International GmbH, 2010.

  36. Littlejohn III TW, Majul CR, Olvera R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009 Apr; 11(4): 207–13.

    Article  CAS  Google Scholar 

  37. Littlejohn T, Majul C, Oigman W, et al. Superior antihypertensive efficacy of the combination of telmisartan and amlodipine versus respective monotherapies in patients with hypertension: results of a factorial design study [abstract no. PS32/WED/39]. J Hypertens 2008; 26 Suppl. 1: S460. Plus poster presented at the 18th European Meeting on Hypertension; 2008 Jun 14–19; Berlin.

    Google Scholar 

  38. Littlejohn III TW, Majul CR, Olvera R, et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4×4 factorial study. Postgrad Med 2009 Mar; 121(2): 5–14.

    Article  PubMed  Google Scholar 

  39. Littlejohn III T, Dahlöf B, Chrysant SG, et al. Combination of telmisartan with amlodipine provides an effective treatment option for elderly patients: sub-analysis from a factorial design study [abstract no. P26.310]. J Hypertens 2009; 27 Suppl. 3: S274.

    Google Scholar 

  40. Littlejohn T, Graff A, Punzi H, et al. Efficacy of telmisartan in combination with amlodipine in hypertensive patients according to race: sub-analysis from a factorial design study [abstract no. P-50]. J Clin Hypertens 2009; 11 Suppl. A (4): A37.

    Google Scholar 

  41. Littlejohn T, Graff A, Majul CR, et al. Efficacy of telmisartan in combination with amlodipine in hypertensive patients from Latin and North America: sub-analysis from a factorial design study [abstract no. P-48]. J Clin Hypertens 2009; 11 Suppl. A (4): A36.

    Google Scholar 

  42. Littlejohn III T, Ruilope LM, Raskin P, et al. Telmisartan in combination with amlodipine provides a highly effective and well tolerated treatment option for hypertensive patients with diabetes: sub-analysis from a factorial design study [abstract no. P26.313]. J Hypertens 2009; 27 Suppl. 3: S275.

    Google Scholar 

  43. Littlejohn III T, Ruilope LM, Chrysant SG, et al. Efficacy of telmisartan in combination with amlodipine in obese hypertensive patients: sub-analysis from a factorial design study [abstract no. P26.305]. J Hypertens 2009; 27 Suppl. 3: S272.

    Google Scholar 

  44. Littlejohn III T, Dahlöf B, Punzi H, et al. Telmisartan in combination with amlodipine is effective in both treatment-naive and previously treated hypertensive patients: sub-analysis from a factorial design study [abstract no. P26.321]. J Hypertens 2009; 27 Suppl. 3: S277.

    Google Scholar 

  45. Littlejohn III T, Dahlöf B, Chrysant SG, et al. Telmisartan and amlodipine in combination provide an effective treatment option for patients with elevated systolic BP: sub-analysis from a factorial design study [abstract no. P26.312]. J Hypertens 2009; 27 Suppl. 3: S274–5.

    Google Scholar 

  46. White WB, Littlejohn TW, Majul CR, et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1–2 hypertension. Blood Press Monit 2010 Aug; 15(4): 205–12.

    Article  PubMed  Google Scholar 

  47. Littlejohn III T, Mancia G, Christensen S, et al. Telmisartan and amlodipine in combination are effective at lowering 24-hour BP in elderly hypertensive patients and those with elevated SBP: findings of an ABPM sub-study [abstract no. P26.308]. J Hypertens 2009; 27 Suppl. 3: S273.

    Google Scholar 

  48. Littlejohn III T, Mancia G, Guthrie R, et al. Telmisartan and amlodipine in combination are effective at lowering 24-hour BP in diabetic and obese hypersensitive patients: findings of an ABPM sub-study [abstract no. P26.307]. J Hypertens 2009; 27 Suppl. 3: S273.

    Google Scholar 

  49. Littlejohn III T, Mancia G, Guthrie R, et al. Telmisartan and amlodipine in combination are effective at lowering 24-hour BP in Black and Latin American hypertensive patients: findings of an ABPM sub-study [abstract no. P26.322]. J Hypertens 2009; 27 Suppl. 3: S278.

    Google Scholar 

  50. Neutel J, Mancia G, Black H, et al. Single-pill combination of telmisartan 80mg/amlodipine 10mg provides superior blood pressure reductions in patients with severe hypertension: TEAMSTA severe HTN study [abstract no. HT. 1.04]. J Hypertens 2010 Jun; 28 e-Suppl. A: e46. Plus poster presented at the 25th Annual Scientific Meeting of the American Society of Hypertension; 2010 May 1–4.

  51. Neldam S, Lang M, TEAMSTA-5 Study Investigators. Fixed-dose combination therapy with telmisartan and amlodipine 5mg in non-responders to amlodipine 5mg provides superior blood pressure reductions to, and is better tolerated than, amlodipine 10mg [abstract no. P26.309]. J Hypertens 2009; 27 Suppl. 3: S273–274. Plus poster presented at the 19th European Meeting on Hypertension; 2009 Jun 12–16; Milan.

    Google Scholar 

  52. Boehringer Ingelheim International GmbH. Telmisartan plus amlodipine study in amlodipine 5mg non-responders in hypertension: TEAMSTA-5 (clinical trial results database; trial no. 1235.5) [online]. Available from URL: http://trials.boehringer-ingelheim.com/com/Home/TrialResults/index.jsp [Accessed 2010 Apr 19].

  53. Boehringer Ingelheim International GmbH. A randomised, double-blind trial to compare telmisartan 40mg plus amlodipine 5mg fixed-dose combination to amlodipine 5mg monotherapy in patients not controlled with amlodipine 5mg monotherapy (clinical trial results database; trial no. 1235.13) [online]. Available from URL: http://trials.boehringer-ingelheim.com/com/Home/ TrialResults/index.jsp [Accessed 2010 Apr 19].

  54. Neldam S, Edwards C, TEAMSTA-10 Study Investigators. Switch to a fixed-dose combination therapy with telmisartan and amlodipine provides significant blood pressure reduction and control in patients not adequately controlled with amlodipine 10mg [abstract no. P26.319]. J Hypertens 2009; 27 Suppl. 3: S277. Plus poster presented at the 19th European Meeting on Hypertension; 2009 Jun 12–16; Milan.

    Google Scholar 

  55. Boehringer Ingelheim International GmbH. Telmisartan plus amlodipine study in amlodipine 10mg non-responders in hypertension: TEAMSTA-10 (clinical trial results database; trial no. 1235.6) [online]. Available from URL: http://trials.boehringer-ingelheim.com/com/Home/TrialResults/index.jsp [Accessed 2010 Apr 19].

  56. Boehringer Ingelheim International GmbH. A randomised, double-blind trial to compare telmisartan 40mg plus amlodipine 5mg fixed-dose combination to telmisartan 40mg monotherapy in patients not controlled with telmisartan 40mg monotherapy (clinical trial results database; trial no. 1235.14) [online]. Available from URL: http://trials.boehringer-ingelheim.com/com/Home/ TrialResults/index.jsp [Accessed 2010 Apr 19].

  57. Neldam S, Lang M, Jones R. Long-term efficacy and safety profile of single-pill combinations of telmisartan/amlodipine in patients not controlled on amlodipine 5mg: open-label follow-up of TEAMSTA-5 [abstract plus poster]. 20th European Meeting on Hypertension; 2010 Jun 18–21; Oslo.

    Google Scholar 

  58. Neldam S, Edwards C, Jones R. Long-term efficacy and safety profile of singlepill combinations of telmisartan/amlodipine in patients not controlled on amlodipine 10mg: open-label follow-up of TEAMSTA-10 [abstract plus poster]. 20th European Meeting on Hypertension; 2010 Jun 18–21; Oslo.

    Google Scholar 

  59. Boehringer Ingelheim Pharmaceuticals. Telmisartan (Micardis) and amlodipine (Norvasc) — factorial design study for the treatment of hypertension [ClinicalTrials.gov identifier NCT00281580]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 May 20].

  60. Boehringer Ingelheim. European Medicines Agency approves Twynsta® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours [media release]. 2010 Oct 12.

Download references

Acknowledgments and Disclosures

The manuscript was reviewed by: C. Borghi, Department of Cardiology, University of Bologna, Bologna, Italy; R. Guthrie, Department of Emergency Medicine, Ohio State University, Columbus, Ohio, USA.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Marit D. Moen

Authors
  1. Marit D. Moen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marit D. Moen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moen, M.D. Telmisartan/Amlodipine. Am J Cardiovasc Drugs 10, 401–412 (2010). https://doi.org/10.2165/11204880-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11204880-000000000-00000

Keywords

Search

Navigation